

#25  
gnd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

GLENN et al.

Appln. No. 09/266,803

Filed: March 12, 1999

Atty. Ref.: 4057-8

Group Art Unit: 1644

Examiner: G. Ewoldt

FOR: ADP-RIBOSYLATING EXOTOXIN USED FOR TRANSCUTANEOUS  
IMMUNIZATION

\* \* \*

INFORMATION DISCLOSURE STATEMENT

February 14, 2002

Hon. Commissioner for Patents  
Washington, D.C. 20231

Sir:

Attached is Form PTO-1449 listing the documents previously submitted for the Examiner's consideration. This form supersedes those used in the past and might prevent confusion when this application is allowed and printed.

This Information Disclosure Statement (IDS) is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.


RECEIVED  
FEB 20 2002  
TECH CENTER 1600/2900

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per MPEP § 609, are earnestly solicited.

The Examiner is invited to contact the undersigned if further information is needed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:   
\_\_\_\_\_  
Gary R. Tanigawa  
Reg. No. 43,180

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100